The refinancing removes near-term liquidity pressure and extends the runway through the Phase 3 4WARD trial readout in H1 2028. However, the $15M conversion feature introduces potential dilution at $3.2341/share, and the revenue covenant starting April 2029 creates a binary risk tied to commercial launch success. Monitor enrollment completion by year-end 2026 and any K2HV draws on the second tranche.
Price Chart
Executive Summary
X4 Pharmaceuticals entered into a $150M senior secured term loan facility with K2 HealthVentures, receiving an $80M first tranche used to repay $78.7M in outstanding obligations under its prior Hercules Capital loan. The new facility provides a longer interest-only period through October 2029, a 48-month maturity, and access to an additional $70M tranche subject to lender approval. The refinancing extends the company's cash runway and removes restrictive covenants from the prior Hercules loan, but introduces new financial covenants tied to cash reserves and future product revenue, with a potential $15M conversion feature into common stock at $3.2341/share.
Key Financial Metrics
Key Facts
- New $150M senior secured term loan facility with K2 HealthVentures, $80M funded at closing on October 7, 2026
- $78.7M used to repay Hercules Capital loan in full ($75M principal + fees), terminating that agreement
- Interest-only period through October 1, 2029, extendable to maturity upon first U.S. commercial sales of mavorixafor in chronic neutropenia
- Cash interest at greater of 8.55% or prime rate + 1.55%, plus 1.0% PIK interest; matures October 1, 2030
- Lenders can convert up to $15M of principal into common stock at $3.2341 per share
- Financial covenants: maintain cash ≥75% of outstanding obligations when market cap <$800M (drops to 40% under conditions); from April 2029, trailing 3-month net product revenue ≥50% of board-approved projections
- Expects to complete Phase 3 4WARD trial enrollment by year-end 2026, with topline data in H1 2028
Financial Impact
Refinancing of $78.7M Hercules debt with $80M new facility; total facility size increased to $150M with $70M additional tranche available; potential $15M equity conversion at $3.2341/share
Risk Factors
- Revenue covenant starting April 2029 requires 50% of board-approved net product revenue projections — failure could trigger default
- Potential $15M equity conversion at $3.2341/share creates dilution overhang
- Variable interest rate (prime + 1.55%) exposes to rising rate environment
- Second $70M tranche is discretionary and subject to lender approval — not guaranteed
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001501697-26-000081 |
| Exhibit: ex991pressreleasedatedocto.htm | 0001501697-26-000081 |
| Document: 0001501697-26-000081-index-headers.html | 0001501697-26-000081 |
| Document: 0001501697-26-000081-index.html | 0001501697-26-000081 |
| Document: 0001501697-26-000081.txt | 0001501697-26-000081 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 19d ago | 8-K | $2.91 | awaiting T+20 | — | $3.25 (+11.68%) |
Oct 7, 2026 20d ago | SC 13G/A | $2.81 | awaiting T+20 | — | $3.25 (+15.66%) |
Oct 1, 2026 26d ago | 144 | $2.83 | awaiting T+20 | — | $3.25 (+14.84%) |
Sep 21, 2026 5w ago | SC 13G | $3.43 $3.02 | ▼ −11.95% | ▼ −11.39% | $3.25 (−5.25%) |
Sep 8, 2026 7w ago | 8-K | $3.51 $2.77 | ▼ −20.97% | ▼ −22.68% | $3.25 (−7.28%) |
Aug 13, 2026 10w ago | Insider Cluster | $4.22 $3.62 | ▼ −14.22% | ▼ −12.23% | $3.25 (−22.99%) |
Aug 13, 2026 10w ago | 144 | $4.29 $3.50 | ▼ −18.41% | ▼ −16.67% | $3.25 (−24.24%) |
Jun 11, 2026 19w ago | Institutional Cluster | $3.88 $3.96 | ▲ +2.06% | ▲ +0.17% | $3.25 (−16.24%) |
Jun 11, 2026 19w ago | Institutional Cluster | $3.88 $3.96 | ▲ +2.06% | ▲ +0.17% | $3.25 (−16.24%) |
May 18, 2026 23w ago | EFFECT | $3.68 $4.04 | ▲ +9.78% | ▲ +8.20% | $3.25 (−11.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers